Completed
Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children
What is being tested
bimatoprost ophthalmic solution 0.03%
+ Vehicle Sterile Solution
Drug
Who is being recruted
Alopecia+3
+ Alopecia Areata
+ Hair Diseases
From 5 to 17 Years
+8 Eligibility Criteria
How is the trial designed
Treatment Study
Placebo-ControlledPhase 4
Interventional
Study Start: June 2010
Summary
Principal SponsorAllergan
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Study start date: June 1, 2010
Actual date on which the first participant was enrolled.This study will evaluate the safety and efficacy of bimatoprost solution 0.03% once daily application to the upper eyelid margins compared with vehicle in treating eyelash loss or hypotrichosis (inadequate or not enough eyelashes) in children.
Official TitleSafety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children
Principal SponsorAllergan
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
71 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.From 5 to 17 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
AlopeciaAlopecia AreataHair DiseasesHypotrichosisSkin DiseasesSkin and Connective Tissue Diseases
Criteria
3 inclusion criteria required to participate
Children who have inadequate eyelashes or have lost their eyelashes as a result of chemotherapy treatment, who completed their chemotherapy (intensive treatment) at least 4 weeks before starting the study, are considered to be at low risk for relapse of their cancer, and are well enough to complete the study
Children who have minimal to moderate inadequate eyelashes due to alopecia areata
Adolescents between the ages of 15-17 years who have minimal to marked inadequate eyelashes
5 exclusion criteria prevent from participating
Any eye disease or abnormality, eye surgery, permanent eyeliner, eyelash implants.
Semi-permanent eyelash tint, dye or eyelash extension application within 3 months
Use of over the counter eyelash growth products within 6 months.
Use of prescription eyelash growth products (eg, Latisse®)
Show More Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Treatment Groups
Study Objectives
2 intervention groups are designated in this study
50% chance of being blinded to the placebo group
Treatment Groups
Group I
Active ComparatorOne drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
Group II
PlaceboOne drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has no location dataSave this study to your profile to know when the location data is available.
CompletedNo study centers